Table 1 Participant characteristics in the MYHAT-NI cohort
MYHAT-NI (Baseline) | MYHAT-NI (2-year visit) | |||||||
|---|---|---|---|---|---|---|---|---|
Total | Aβ PET – | Aβ PET + | p-valuea | Total | Aβ PET – | Aβ PET + | p-valuea | |
N (%) | 113 | 85 (75.2%) | 28 (24.8%) | 63 | 42 (66.7%) | 21 (33.3%) | ||
Age (years) | 76.0 (72.0 – 80.3) | 75.0 (71.0 – 79.3) | 79.0 (73.5 – 82.5) | 0.055 | 77.0 (74.0 – 81.8) | 76.0 (74.0 – 81.0) | 78.0 (73.8 – 82.3) | 0.884 |
Sex | 0.275 | 0.109 | ||||||
Female (%) | 61 | 43 (70.5%) | 18 (29.5%) | 32 | 18 (56.3%) | 14 (43.7%) | ||
Male (%) | 52 | 42 (80.8%) | 10 (19.2%) | 31 | 24 (77.4%) | 7 (22.6%) | ||
Education (years) | 12 (12 – 16) | 12 (12 – 16) | 13 (12 – 15) | 0.583 | 13 (12 – 16) | 14 (12 – 16) | 12 (12 – 14) | 0.050 |
Years between visits | 2.4 (2.2 – 2.6) | 2.4 (2.2 – 2.6) | 2.4 (2.2 – 2.7) | 0.358 | ||||
Race | 1.000 | 1.000 | ||||||
Non-Hispanic White | 107 | 80 (74.8%) | 27 (25.2%) | 60 | 40 (66.7%) | 20 (33.3%) | ||
Black/African American | 6 | 5 (83.3%) | 1 (16.7%) | 3 | 2 (66.7%) | 1 (33.3%) | ||
MMSEb | 0.430 | 1.000 | ||||||
> = 24 | 108 | 81 (75.0%) | 27 (25.0%) | 38 | 26 (68.4%) | 12 (31.6%) | ||
19—23 | 4 | 3 (7.0) | 1 (25.0%) | 0 | 0 | 0 | ||
CDRc | 0.015 | 0.033 | ||||||
CDR = 0 | 102 | 80 (78.2%) | 22 (21.8%) | 54 | 39 (72.7%1 | 15 (27.3%) | ||
CDR = 0.5 | 10 | 4 (40.0%) | 6 (60.0%) | 5 | (20.0%) | 4 (80.0%) | ||
APOE ε4 carrier | < 0.001 | 0.014 | ||||||
Yes | 18 | 6 (33.3%) | 12 (66.7%) | 12 | 4 (33.3%) | 8 (66.7%) | ||
No | 95 | 79 (83.2%) | 16 (16.8%) | 51 | 38 (74.5%) | 13 (25.5%) | ||
Tau PETd | < 0.001 | 0.001 | ||||||
Negative | 74 | 65 (87.8%) | 9 (12.2%) | 42 | 34 (81.0%) | 8 (19.0%) | ||
Positive | 39 | 20 (51.3%) | 19 (48.7%) | 21 | 8 (38.1%) | 13 (61.9%) | ||
N Statuse | 0.639 | 0.395 | ||||||
Negative | 80 | 59 (73.8%) | 21 (26.3%) | 42 | 26 (61.9%) | 16 (38.1%) | ||
Positive | 33 | 26 (78.8%) | 7 (21.2%) | 20 | 15 (75.0%) | 5 (25.0%) | ||